Literature DB >> 8265610

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.

J A Mitchell1, P Akarasereenont, C Thiemermann, R J Flower, J R Vane.   

Abstract

Constitutive cyclooxygenase (COX-1; prostaglandin-endoperoxide synthase, EC 1.14.99.1) is present in cells under physiological conditions, whereas COX-2 is induced by some cytokines, mitogens, and endotoxin presumably in pathological conditions, such as inflammation. Therefore, we have assessed the relative inhibitory effects of some nonsteroidal antiinflammatory drugs on the activities of COX-1 (in bovine aortic endothelial cells) and COX-2 (in endotoxin-activated J774.2 macrophages) in intact cells, broken cells, and purified enzyme preparations (COX-1 in sheep seminal vesicles; COX-2 in sheep placenta). Similar potencies of aspirin, indomethacin, and ibuprofen against the broken cell and purified enzyme preparations indicated no influence of species. Aspirin, indomethacin, and ibuprofen were more potent inhibitors of COX-1 than COX-2 in all models used. The relative potencies of aspirin and indomethacin varied only slightly between models, although the IC50 values were different. Ibuprofen was more potent as an inhibitor of COX-2 in intact cells than in either broken cells or purified enzymes. Sodium salicylate was a weak inhibitor of both COX isoforms in intact cells and was inactive against COX in either broken cells or purified enzyme preparations. Diclofenac, BW 755C, acetaminophen, and naproxen were approximately equipotent inhibitors of COX-1 and COX-2 in intact cells. BF 389, an experimental drug currently being tested in humans, was the most potent and most selective inhibitor of COX-2 in intact cells. Thus, there are clear pharmacological differences between the two enzymes. The use of such models of COX-1 and COX-2 activity will lead to the identification of selective inhibitors of COX-2 with presumably less side effects than present therapies. Some inhibitors had higher activity in intact cells than against purified enzymes, suggesting that pure enzyme preparations may not be predictive of therapeutic action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8265610      PMCID: PMC48050          DOI: 10.1073/pnas.90.24.11693

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs.

Authors:  F L Lanza
Journal:  Scand J Gastroenterol Suppl       Date:  1989

2.  Streptococcal M protein.

Authors:  V A Fischetti
Journal:  Sci Am       Date:  1991-06       Impact factor: 2.142

Review 3.  Thermoregulatory actions of eicosanoids in the central nervous system with particular regard to the pathogenesis of fever.

Authors:  A S Milton
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

Review 4.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

5.  Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.

Authors:  J A Maier; T Hla; T Maciag
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

6.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

Authors:  J Y Fu; J L Masferrer; K Seibert; A Raz; P Needleman
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

7.  Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells.

Authors:  K K Wu; R Sanduja; A L Tsai; B Ferhanoglu; D S Loose-Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

8.  An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species.

Authors:  K D Rainsford
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

9.  Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled.

Authors:  G de Nucci; R J Gryglewski; T D Warner; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents.

Authors:  R J Kulmacz; W E Lands
Journal:  J Biol Chem       Date:  1985-10-15       Impact factor: 5.157

View more
  273 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Treatment advances in rheumatoid arthritis.

Authors:  E R Arriola; N P Lee
Journal:  West J Med       Date:  1999-05

3.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Calpain inhibitor I reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; I Serraino; L Dugo; D Britti; G Mazzullo; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 5.  Aspirin-induced asthma.

Authors:  L T Vaszar; D D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

Review 6.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 8.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 9.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 10.  Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

Authors:  Timothy D Warner; Jane A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.